Green Valley Pharmaceuticals

Executive Summary

Green Valley Pharmaceuticals is a Chinese biopharmaceutical leader in neuroscience, best known for developing Oligomannate (GV-971), the first new Alzheimer's drug approved in China in decades. The company has successfully commercialized GV-971 domestically and is now focused on expanding its footprint globally, with ongoing clinical trials in the U.S. and Europe. Beyond Alzheimer's, Green Valley is advancing a pipeline targeting Parkinson's disease and neuroinflammation, leveraging its expertise in carbohydrate-based therapeutics. The company benefits from strong government support for neurodegenerative research and a large aging population in China, which provides a substantial domestic market. However, challenges include regulatory hurdles abroad, potential competition from new Alzheimer's therapies (e.g., lecanemab), and the need to demonstrate robust efficacy in diverse populations. Financially, Green Valley is publicly traded but with limited liquidity, and its valuation is tied closely to GV-971's commercial performance and pipeline progress. The company's strategic partnerships and R&D investments position it for long-term growth, but near-term volatility remains due to clinical data readouts and regulatory decisions.

Upcoming Catalysts (preview)

• Q4 2026U.S. Phase 3 Top-Line Data for GV-971 in Alzheimer's Disease60% success
• Q2 2026Initiation of Phase 2 Trial for GV-971 in Parkinson's Disease70% success
• Q3 2026Regulatory Approval in Additional Asian Markets (e.g., South Korea, Taiwan)80% success